Supportive Care for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to understand how older adults cope with chemotherapy by examining their resilience and personalizing care plans. Researchers will use an Electronic Frailty Index, a tool to measure vulnerability, to guide supportive care through an Electronic Frailty Index-Directed Care Pathway. This approach aims to reduce chemotherapy side effects. The trial suits individuals aged 65 or older with an active cancer diagnosis who are about to start chemotherapy and have been identified as pre-frail or frail. Participants will receive education and referrals for additional support to better manage their treatment. As an unphased trial, this study offers participants the chance to contribute to advancements in personalized care for older adults undergoing chemotherapy.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It focuses on patients who are about to start chemotherapy, so it's best to discuss your current medications with the trial team.
What prior data suggests that the Electronic Frailty Index-Directed Care Pathway is safe for older adults receiving chemotherapy?
Research has shown that the Electronic Frailty Index (eFI) aids in understanding how older adults might respond to chemotherapy. This tool predicts the likelihood of experiencing problems from cancer treatments by assessing various health factors, such as existing conditions.
Regarding safety, the eFI is not a treatment. Instead, it customizes care to better fit each person's needs, potentially reducing complications from chemotherapy. This approach is generally well-received because it supports patients rather than directly treating them. No reports indicate that the eFI causes harm. Instead, it helps healthcare providers make informed decisions to improve patient care.12345Why are researchers excited about this trial?
Researchers are excited about the Electronic Frailty Index-Directed Care Pathway because it offers a personalized approach to managing chemotherapy toxicity in older cancer patients. Unlike standard care options, which might not consider individual frailty levels, this pathway uses a detailed assessment to tailor supportive care. By identifying frail or pre-frail patients, the treatment aims to reduce chemotherapy side effects through targeted interventions, potentially improving both the quality of life and treatment outcomes for this vulnerable group.
What evidence suggests that the Electronic Frailty Index-Directed Care Pathway is effective for supportive care in cancer patients?
Research has shown that the Electronic Frailty Index (eFI) can predict how well older adults might cope with chemotherapy. In this trial, participants aged 65 or older with an active cancer diagnosis and planned chemotherapy will undergo assessment using the eFI. Studies have found that the eFI effectively predicts 30-day survival rates in patients with cancers such as breast and colon cancer. It identifies frailty—weakness or vulnerability due to aging or illness—more accurately than age alone. This allows for more precise customization of care, potentially reducing side effects from cancer treatments. Although more research is needed, early results suggest it could significantly improve care for older cancer patients.13678
Who Is on the Research Team?
Heidi Klepin, MD
Principal Investigator
Wake Forest University Health Sciences
Are You a Good Fit for This Trial?
This trial is for adults aged 65 and older who are undergoing chemotherapy. It aims to understand their needs better by assessing resilience and creating personalized care plans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline assessment and receive results regarding their frailty, with referrals for supportive care interventions
Chemotherapy and Symptom Reporting
Participants receive chemotherapy and participate in weekly symptom reporting via electronic survey and phone call
Follow-up
Follow-up assessments are completed, and a subset of participants and providers are interviewed for feedback on the intervention
What Are the Treatments Tested in This Trial?
Interventions
- Electronic Frailty Index-Directed Care Pathway
Trial Overview
The intervention being studied is a supportive care approach that uses an electronic frailty index to guide the creation of individualized care pathways for elderly patients receiving chemotherapy.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants aged 65 or older with an active cancer diagnosis who are planned to receive chemotherapy and are eFI pre-frail or frail. Participants will be provided with results and education regarding baseline assessments and offered referrals for supportive care interventions to decrease chemotherapy toxicity
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Atrium Health Wake Forest Baptist
Collaborator
Atrium Health Wake Forest Baptist
Collaborator
Citations
Resilience Enhancement Using Electronic Frailty Index ...
This is a prospective single-arm intervention trial of patients aged 65 or older with an active cancer diagnosis who are planned to receive ...
Electronic frailty index predicts 30-day mortality from ...
The eFI closely predicts poor outcomes from SACT, particularly in early breast and colon cancer, and requires further evaluation in a prospective study.
Frailty Index, Not Age, Predicts Treatment Outcomes and ...
The median FI (IQR) was 0.24 (0.15–0.31) and 43% were frail (FI>0.25). FI was positively correlated with ECOG, however 28% of ECOG 0–1 were frail. In ...
Frailty and Cancer: Current Perspectives on Assessment ...
This review describes the current standards and perspectives for the assessment and monitoring of frailty in elderly patients with cancer.
Frailty and outcomes in adults undergoing systemic anticancer ...
This review and meta-analysis summarizes existing evidence evaluating the association between baseline frailty assessment tools and systemic anticancer ...
Electronic Frailty Index: A risk stratification tool for survival ...
Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer.
Challenges and opportunities to developing a frailty index ...
Frailty indices can be developed from varied data sources including elements captured in EHRs, such as comorbidities, laboratory values, and assessments of ...
8.
cancernetwork.com
cancernetwork.com/view/new-frailty-index-associated-outcomes-older-patients-chemotherapyNew Frailty Index Associated With Outcomes in Older ...
That index was found to be associated with outcomes both related to chemotherapy toxicity and to age-related outcomes.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.